Document Detail


Effect of waxy maize-derived hydroxyethyl starch 130/0.4 on renal function in surgical patients.
MedLine Citation:
PMID:  23340352     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The aim of this meta-analysis was to evaluate renal safety with the active substance of the latest generation of waxy maize-derived hydroxyethyl starch in surgical patients. The authors focused on prospective, randomized, controlled studies that documented clinically relevant variables with regard to renal effects of waxy maize-derived hydroxyethyl starch 130/0.40.
MATERIALS AND METHODS: The authors carefully searched for all available prospective, randomized studies and evaluated the greatest delta from baseline values in renal safety variables (serum creatinine values, calculated creatinine clearance, incidence of renal replacement therapy, and acute renal failure). The authors included 17 studies that analyzed patients (n = 1,230) undergoing a variety of surgical procedures.
RESULTS: For maximum serum creatinine values, the effect size estimate was 0.068 (95% CI = -0.227 to 0.362), P = 0.65. For calculated creatinine clearance values, pooled risk difference was 0.302 (95% CI = -0.098 to 0.703), P = 0.14. For incidence of acute renal failure, pooled risk difference was 0.0003 (95% CI = -0.018 to 0.019), P = 0.98. For incidence of renal replacement therapy, pooled risk difference was -0.003 (95% CI = -0.028 to 0.022), P = 0.85.
CONCLUSIONS: The authors found no evidence for renal dysfunction caused by modern waxy maize-derived hydroxyethyl starch 130/0.40 in surgical patients.
Authors:
Claude Martin; Matthias Jacob; Eric Vicaut; Bertrand Guidet; Hugo Van Aken; Andrea Kurz
Publication Detail:
Type:  Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Anesthesiology     Volume:  118     ISSN:  1528-1175     ISO Abbreviation:  Anesthesiology     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-23     Completed Date:  2013-07-08     Revised Date:  2013-10-07    
Medline Journal Info:
Nlm Unique ID:  1300217     Medline TA:  Anesthesiology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  387-94     Citation Subset:  AIM; IM    
Affiliation:
Département d'Anesthésie et de Réanimation, CHU Nord, Assistance Publique-Hôpitaux de Marseille, Marseille cedex, France. claude.martin@ap-hm.fr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Kidney Injury / epidemiology,  physiopathology
Creatinine / blood
Endpoint Determination
Hetastarch / adverse effects*
Humans
Kidney / physiology*
Kidney Diseases / chemically induced*,  physiopathology
Kidney Function Tests
Length of Stay
Perioperative Care
Plasma Substitutes / adverse effects*
Randomized Controlled Trials as Topic
Risk Assessment
Zea mays / chemistry*
Chemical
Reg. No./Substance:
0/Plasma Substitutes; 60-27-5/Creatinine; 9005-27-0/Hetastarch
Comments/Corrections
Comment In:
Anesthesiology. 2013 Sep;119(3):736-7   [PMID:  23962944 ]
Anesthesiology. 2013 Sep;119(3):733-5   [PMID:  23962942 ]
Anesthesiology. 2013 Sep;119(3):735-6   [PMID:  23962943 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A Double-blind Randomized Trial of Wound and Intercostal Space Infiltration with Ropivacaine during ...
Next Document:  Nerve Injury-related Autoimmunity Activation Leads to Chronic Inflammation and Chronic Neuropathic P...